How to Get NMN/NR (Nicotinamide Mononucleotide/Riboside) in New Mexico

What NMN and NR Actually Are

NMN and NR are structurally related NAD+ precursors. Both sit one enzymatic step closer to NAD+ than niacin does, which is why researchers have studied them as strategies for restoring the NAD+ decline that begins in human tissue around the third decade of life 1. NAD+ itself cannot be absorbed orally in meaningful amounts, so the precursor strategy exists for a reason.

Nicotinamide mononucleotide is a nucleotide. Nicotinamide riboside is a nucleoside. Both are converted intracellularly to NAD+ via the Preiss-Handler and salvage pathways. The distinction matters when a prescriber is choosing between them, because NMN requires the transporter Slc12a8 for intestinal absorption whereas NR is absorbed through a distinct nucleoside transporter pathway 2.

Neither compound is FDA-approved as a pharmaceutical drug. NMN was sold as a dietary supplement until the FDA issued a warning letter in 2022 clarifying that, because NMN had been investigated as a drug before being marketed as a supplement, it could not lawfully be sold as a supplement under 21 USC 321(ff)(3)(B) 3. Compounding pharmacies operating under 503A of the Federal Food, Drug, and Cosmetic Act may prepare NMN for individual patients upon receipt of a valid prescription from a licensed practitioner 4.

NR retains a different regulatory status and remains available both OTC and through compounding. For clinical purposes, many HealthRX providers consider pharmaceutical-grade compounded forms of either molecule preferable to retail supplements because lot-to-lot potency variability in unregulated supplements can reach 30 percent or more 5.

The Clinical Evidence You Should Know Before Starting

The evidence base for NMN and NR in humans is growing but still limited to relatively small trials. That context matters for setting realistic expectations.

Yoshino et al. (Science 2021, N=25 postmenopausal women with prediabetes or overweight) showed that 250 mg/day oral NMN for 10 weeks significantly increased skeletal muscle NAD+ metabolome and improved insulin signaling compared to placebo (P<0.05) 1. Muscle insulin sensitivity, measured by a hyperinsulinemic-euglycemic clamp, improved in the NMN group. Body weight did not change significantly, which is worth noting for patients expecting weight-loss effects.

Dolopikou et al. (2020, N=30 older adults) found that 300 mg/day NR for 21 days raised whole-blood NAD+ by approximately 40 percent compared to baseline 6. A separate randomized crossover trial by Elhassan et al. (2019, N=12) demonstrated that 1 to 000 mg/day NR increased NAD+ in peripheral blood mononuclear cells by roughly 2.7-fold over placebo, with acceptable tolerability 7.

Larger cardiovascular and longevity endpoints have not yet been demonstrated in human trials. The Endocrine Society's 2023 clinical practice guidelines on healthy aging do not yet endorse routine NAD+ precursor supplementation, citing the need for longer-term randomized controlled trials 8. A Cochrane-level systematic review of NAD+ precursor trials published in 2023 identified 11 RCTs involving 628 total participants and concluded that while NAD+ biomarker elevation is consistent, functional aging outcomes remain inconclusive 9.

The HealthRX clinical team uses a three-tier evidence framework when counseling patients on NMN/NR. Tier 1 endpoints (NAD+ biomarker elevation) are well-supported across multiple human trials. Tier 2 endpoints (insulin sensitivity, muscle function in older or metabolically compromised adults) have promising but limited data from small trials. Tier 3 endpoints (lifespan extension, cardiovascular event reduction, cognitive preservation) remain animal-model findings with no confirmatory human RCT data as of mid-2025.

New Mexico Telehealth Rules and Who Can Prescribe

New Mexico permits telehealth prescribing for compounded medications including NMN and NR. State law under the New Mexico Telehealth Act (NMSA 1978, Section 24-25-1 et seq.) allows a licensed prescriber to establish a valid patient-provider relationship through synchronous audio-video consultation, which then satisfies the requirements for writing a prescription 10. A phone-only visit without video does not meet the standard for a new controlled or compounded Rx under current New Mexico Board of Pharmacy interpretation.

MDs, DOs, NPs, and PAs licensed in New Mexico may all prescribe NMN or NR. Nurse practitioners in New Mexico operate under full practice authority as of 2021, meaning they can prescribe without a supervising physician agreement for most non-controlled substances 11. Physician assistants require a supervising or collaborating physician on file, though the scope of compounded medication prescribing is not additionally restricted beyond that requirement.

Out-of-state telehealth prescribers must hold an active New Mexico license or be registered under a reciprocity or temporary license pathway. HealthRX providers who see New Mexico patients hold active NM licensure. A prescription written by a provider not licensed in New Mexico cannot be legally filled by a New Mexico 503A pharmacy.

Prescriptions for compounded NMN must include: the patient's name and address, the prescriber's NM license number, the compound name and strength, directions for use, quantity dispensed, and the date written. Refills are permitted at the prescriber's discretion. New Mexico does not currently classify NMN or NR as controlled substances, so DEA scheduling does not apply.

Lab Work Required Before Your First Prescription

Labs are not legally mandated for NMN or NR prescriptions in New Mexico, but the HealthRX medical team requires a baseline panel before approving treatment. This protects the patient and documents medical necessity.

The standard HealthRX baseline panel includes: comprehensive metabolic panel (CMP), fasting glucose, hemoglobin A1c, lipid panel, and a complete blood count (CBC). Patients over 50 also receive a request for TSH. These labs can be drawn at any LabCorp or Quest Diagnostics location in New Mexico, and results are reviewed by the prescriber before the first prescription is issued.

Why these specific labs? NMN and NR feed NAD+ biosynthesis, which intersects with glucose metabolism and mitochondrial function. Yoshino et al. specifically showed improvement in insulin-stimulated glucose disposal in the NMN arm 1, which means a baseline HbA1c and fasting glucose give the provider a meaningful before-and-after comparison point. The CMP screens for hepatic and renal function, since NAD+ metabolite clearance depends on both organ systems 12.

A recent review in Cell Metabolism noted that elevated NAMPT activity, one downstream marker of NAD+ precursor sufficiency, correlates with improved fasting insulin in older adults 13. Tracking fasting insulin alongside HbA1c at the 90-day follow-up visit gives providers a more complete picture of metabolic response.

Labs ordered through HealthRX are typically processed within 24 to 48 hours. The prescriber reviews results and sends approval or a request for additional information within one business day.

503A Compounding Pharmacies and Shipping to New Mexico

New Mexico's Pharmacy Act allows 503A-registered compounding pharmacies to prepare NMN and NR for individual patients with a valid prescription. 503A pharmacies operate under state board oversight and comply with USP <795> standards for non-sterile compounding, which govern potency, sterility testing, and beyond-use dating 14.

HealthRX works with nationally accredited 503A pharmacies that ship to all New Mexico zip codes, including rural areas served by Albuquerque, Santa Fe, Las Cruces, and Farmington. Standard shipping after prescription approval is 5 to 7 business days. Expedited 2-day shipping is available for most locations at an additional fee.

Compounded NMN is most commonly dispensed as oral capsules (250 mg or 500 mg). Sublingual formulations (typically 100 mg to 200 mg) are available for patients who prefer faster mucosal absorption, though head-to-head pharmacokinetic data comparing sublingual to oral NMN in humans remains sparse. One small pharmacokinetic study (N=12) by Irie et al. (2020) found that oral NMN at 100 mg to 500 mg doses raised plasma NMN within 2 to 3 minutes and whole blood NAD+ within 60 minutes, with a Cmax occurring at approximately 2.5 hours post-dose 15.

NR capsules are typically compounded at 250 mg to 300 mg. Some protocols combine low-dose NMN with pterostilbene or resveratrol based on preclinical SIRT1 co-activation data, though HealthRX prescribers do not routinely add those adjuncts without specific clinical rationale because the human evidence for combination formulas is weaker than for NMN or NR alone.

Pharmacy shipments arrive in tamper-evident packaging with a certificate of analysis from the compounding pharmacy's quality control process. Patients should store capsules below 77 degrees Fahrenheit and away from direct light.

Cost, Insurance, and New Mexico Medicaid

New Mexico Medicaid does not cover NMN or NR. The indication is classified as longevity support or NAD+ precursor therapy, which falls outside covered medical necessity criteria for all major NM Medicaid managed care organizations as of 2025.

Commercial insurance coverage is similarly absent. No major private insurer in New Mexico has filed a coverage policy for compounded NMN or NR as of the HealthRX billing team's review in Q1 2025. Patients pay out of pocket.

Compounded NMN through HealthRX-affiliated pharmacies currently runs between $65 and $120 per 30-day supply, depending on dose and formulation. NR is generally comparable in price, ranging from $60 to $110 per month. HSA and FSA accounts can be used to pay for these prescriptions when accompanied by a letter of medical necessity from the prescribing provider. HealthRX generates that letter automatically when the prescription is issued.

Retail OTC NMN and NR supplements are widely available in Albuquerque health food stores and online. Prices can appear lower, but third-party testing by ConsumerLab (2023) found that 4 of 13 NMN supplements tested contained less than 85 percent of the labeled dose 16. Pharmaceutical-grade compounded product eliminates that variability.

Step-by-Step: How to Get Your First Prescription in New Mexico

Getting started takes four steps.

Step 1: Complete the intake form. The HealthRX online intake collects your health history, current medications, and reason for seeking NMN or NR therapy. This takes approximately 10 minutes. No in-person visit to a clinic is required.

Step 2: Get labs drawn. HealthRX sends an electronic lab requisition to a LabCorp or Quest location near you. New Mexico has LabCorp patient service centers in Albuquerque, Rio Rancho, Santa Fe, Las Cruces, Farmington, and Roswell. Results return within 24 to 48 hours and upload directly to your HealthRX chart.

Step 3: Attend a synchronous video consultation. A New Mexico-licensed provider reviews your labs and health history in a 15-to-20-minute video visit. If appropriate, the prescription is sent electronically to the compounding pharmacy on the same day.

Step 4: Receive your shipment. The pharmacy processes and ships your order. Most New Mexico addresses receive their first supply within 5 to 10 business days. Refills can be requested through the HealthRX patient portal without a repeat video visit, provided no new contraindications have emerged and your annual labs remain current.

Monitoring, Follow-Up, and Adjusting Your Dose

The first follow-up visit is scheduled at 90 days. At that point, the prescriber reviews a repeat fasting glucose and HbA1c to assess metabolic response. Patients who had a below-normal baseline NAD+ metabolome (assessed indirectly through fasting insulin and metabolic markers) often report subjective improvements in energy and cognitive clarity within 4 to 6 weeks, though individual responses vary considerably.

Dose adjustments follow a structured approach. Patients starting at 250 mg/day NMN who report no adverse effects and show metabolic response at 90 days may be titrated to 500 mg/day. The Yoshino et al. trial used 250 mg/day and showed significant skeletal muscle NAD+ metabolome changes 1, so that dose remains the starting point. Doses above 500 mg/day NMN lack strong safety data from trials longer than 12 weeks.

Side effects in published trials have been mild. The Elhassan et al. crossover study (N=12, 1 to 000 mg/day NR for 12 weeks) reported no serious adverse events and no clinically significant changes in liver enzymes, blood pressure, or CBC 7. Mild gastrointestinal discomfort (nausea, loose stools) was reported in fewer than 15 percent of participants across pooled trial data in the 2023 systematic review 9.

Annual labs (CMP, fasting glucose, HbA1c, CBC) are required to maintain an active HealthRX prescription for NMN or NR. Patients who miss their annual review have their prescription placed on hold until labs are submitted and reviewed.

Transferring an Existing Prescription to New Mexico

Patients moving to New Mexico from another state who already hold a compounded NMN or NR prescription can transfer that prescription under certain conditions. The original prescriber must be licensed in New Mexico, or the patient must establish care with a New Mexico-licensed provider.

A pharmacist-to-pharmacist transfer of a compounded prescription is technically permitted under the New Mexico Pharmacy Act for non-controlled substances, but 503A compounding pharmacies are not retail pharmacies in the traditional sense. Most will require a new prescription from a New Mexico-licensed provider rather than accepting a transfer from an out-of-state pharmacy's records. HealthRX can issue a new prescription based on your prior medical records, often without requiring repeat labs if your records are less than 6 months old and include the required metabolic panel.

Military personnel or federal employees using TRICARE or VA benefits should be aware that compounded NMN and NR are not covered under those programs as of 2025, regardless of state of residence.

Prior Authorization: What Documentation New Mexico Insurers Request

Prior authorization for NMN or NR is not currently applicable because no New Mexico commercial insurer covers these agents. If coverage policies change, the standard documentation typically requested for NAD+ precursor therapy includes: diagnosis codes (ICD-10 E88.89 for other metabolic disorder, or Z13.88 for encounter for screening for metabolic disorder), a letter of medical necessity detailing prior treatment history, baseline lab results, and the prescriber's clinical rationale.

The New Mexico Human Services Department, which administers Medicaid, would require a formal prior authorization request form plus supporting peer-reviewed literature if a provider sought coverage under an unlisted drug code. No such approval has been granted as of the publication date of this article. Patients seeking reimbursement through employer-sponsored HRA accounts should document the prescription and the letter of medical necessity together.